Regeneron Pharmaceuticals, Inc.

Purdue Research Foundation

Endocyte, Inc.

Bindu Varghese

Andrew J Murphy

Cagan Gurer

O Gavin Thurston

Gavin Thurston

Eric L Smith

Samuel H Davis

Jessica Kirshner

Israel Lowy

Carrie Brownstein

Philip Stewart Low

Iontcho Radoslavov Vlahov

Eric B Smith

Walter Anthony Henne, Jr

Ryan Rothenbuhler

Cagen Gurer

Jessica R Kirshner

Eric Smith

Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRPα gene. Genetically modified mice are described, including mice that express a human or humanized SIRPα protein from an endogenous SIRPα locus.

Non-human animals having a humanized signal-regulatory protein gene

The present invention provides methods for treating, reducing the severity, or inhibiting the growth of cancer (e.g., a B-cell cancer such as Hodgkin's lymphoma or acute lymphoblastic leukemia). The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to programmed death 1 (PD-1) receptor in combination with a therapeutically effective amount of a bispecific antibody that specifically binds to CD20 and CD3.

Combination of anti-PD-1 antibodies and bispecific anti-CD20/anti-CD3 antibodies to treat cancer

The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fc&#x3b3; receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fc&#x3b3; receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other CD20-related diseases and disorders.

Methods and antibody compositions for tumor treatment

Genetically modified non-human animals and methods and compositions for making and using the same are provided, wherein the genetic modification comprises a humanization of an endogenous signal-regulatory protein gene, in particular a humanization of a SIRP&#x3b1; gene. Genetically modified mice are described, including mice that express a human or humanized SIRP&#x3b1; protein from an endogenous SIRP&#x3b1; locus.

The present invention relates to a method (dosage regimen) for administering a CD3&#xd7;CD20 bispecific antibody to a human patient, comprising (a) administering a first dose of said antibody in a specific dosage; and consecutively (b) administering a second dose of said antibody after a period of time, wherein said second dose exceeds said first dose. The methods of the invention (and likewise the dosage regimen of the invention) are also suitable for treating B cell (CD20-positive) cancer in a human patient, or for ameliorating and/or preventing a medical condition mediated by the periodic or continued administration of a CD3&#xd7;CD20 bispecific antibody to a human patient. The present invention also relates to the use of a CD3&#xd7;CD20 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method or treatment regime as defined in any one of the preceding claims. A pharmaceutical package or kit comprising the first dose, the second dose, and any subsequent doses are also part of the present invention.

Methods for tumor treatment using CD3XCD20 bispecific antibody

The invention relates to a method for targeting an imaging agent to cells of an animal to detect localized infections. More particularly, localized infections are detected by targeting imaging agents to inflammatory cells having receptors for a vitamin by using vitamin-imaging agent conjugates.

Method of imaging localized infections

Growing community of inventors

Hopewell Junction, NY, United States of America

Bindu Varghese